12885_2018_4336_MOESM2_ESM.pdf (71.95 kB)
Additional file 2: of Vemurafenib in Chinese patients with BRAFV600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study
journal contribution
posted on 2018-05-03, 05:00 authored by Lu Si, Xiaoshi Zhang, Zhen Xu, Qiudi Jiang, Lilian Bu, Xuan Wang, Lili Mao, Weijiang Zhang, Nicole Richie, Jun GuoFigure S1. Vemurafenib Ctrough concentrations (mean ± SD) after day 28 in the pharmacokinetics and expansion cohorts. SD standard deviation, CV coefficient of variation. (PDF 71 kb)